Technology | November 26, 2014

FDA Clears FFR-CT

Non-invasive computed tomography imaging exam can evaluate coronary blood flow without a diagnostic catheterization

Heartflow's FFR-CT showing coronary blood flow being impacted by a blockage. The system offers a virtual FFR number that has good correlation with invasive, catheter-based FFR.

Photo 1, showing a coronary CT angiography scan of a heavily calcified coronary artery. Photo 2 shows the corresponding CT-FFR.

CT-FFR, FFR-CT

Photo 2, showing HeartFlow's CT-FFR report for the same vessel segment as shown in Photo 1.

November 26, 2014 — The U.S. Food and Drug Administration (FDA) today cleared HeartFlow’s FFR-CT (fractional flow reserve—computed tomography) software, which permits non-invasive evaluation of coronary artery blood flow in patients showing signs of coronary artery disease.  
 
The clearance may open a new era of coronary CT imaging, where a single scan can show blood flow with specific FFR flow rates for all segments in the heart. This may eliminate the need to perform diagnostic catheter angiography or to perform invasive catheter-based FFR tests. FFR-CT shows the exact area of blockages, the impact each has on flow and can help guide treatment and aid in interventional procedural navigation. Coronary CT experts predict the technology also may eliminate the need for myocardial perfusion nuclear imaging and other tests usually performed on patients presenting to emergency departments with chest pain.
 
Coronary artery disease is the leading cause of death for both men and women in the United States. One piece of clinical information healthcare professionals use to determine the extent of a blockage in the heart or a coronary artery is a value called fractional flow reserve (FFR). Obtaining this value requires an invasive cardiac catheterization. 
 
The HeartFlow FFR-CT software can non-invasively provide an estimate of FFR using data from a CT scan of the patient’s heart. Doctors can use the estimate, along with other clinical patient data, to determine the likelihood that the actual FFR is below accepted limits and whether or not a more accurate FFR assessment using cardiac catheterization is necessary. It is expected the technology will greatly reduce the number of patients who are currently sent to the cath lab only to find their blood flow through a partial blockage is normal. 
 
“Heart Flow FFR-CT is a computer modeling program that provides a functional assessment of blood flow in the coronary arteries from detailed anatomical data,” said William Missal, M.D., MPH, deputy director for science and chief scientist in the FDA’s Center for Devices and Radiological Health. “This non-invasive method is an additional tool for clinicians who are considering the risks and benefits of invasive coronary procedures.”
 
The Heart Flow FFR-CT software is housed at HeartFlow Inc.’s headquarters in Redwood City, Calif. A healthcare professional electronically sends the patient’s CT scan data to HeartFlow where a case analyst creates 3-D computer models of different sections of the patient’s heart and runs a blood flow simulator program on the models. After analyzing the data and the models, the case analyst electronically sends a report with the estimated FFR-CT values displayed as color images of the patient’s heart.  
 
The FDA reviewed the data for HeartFlow FFR-CT through the de novo premarket review pathway, a regulatory pathway for some low- to moderate-risk medical devices that are not substantially equivalent to an already legally marketed device.
 
Data submitted to support the safety and effectiveness of HeartFlow FFR-CT included clinical studies that compared FFR-CT measurements to FFR values directly measured by cardiac catheterization on subjects with suspected coronary artery disease who were therefore referred for catheterization and FFR. The results showed that Heart Flow FFR-CT was able to correctly identify 84 percent of the significant blockages identified by FFR as requiring intervention, and 86 percent of blockages identified by FFR as not requiring intervention. The company also submitted data and information showing how they have mitigated risks associated with the device, such as controlling for erroneous calculations that can lead to delayed or improper treatment.
 
Due to the potential impact the technology may have on cardiology, the FDA sent out its own press release on the technology prior to the company releasing any news.
 
 
 
 
For more information: heartflow.com
 

Related Content

Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
News | Advanced Visualization | November 13, 2018
Canon Medical Systems USA and Applied Radiology will host a pair of expert-led forums in high-resolution imaging and...
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Results of the vertebrae-based analysis (383 vertebrae in 34 patients) for detection of BME.

Results of the vertebrae-based analysis (383 vertebrae in 34 patients) for detection of BME.

Sponsored Content | Case Study | Computed Tomography (CT) | November 06, 2018
The following is a summary of a study published in the
The NeuViz 16 Essence from Neusoft Medical Systems.

The NeuViz 16 Essence from Neusoft Medical Systems.

Feature | Computed Tomography (CT) | November 05, 2018 | By Melinda Taschetta-Millane
According to an industry mark...
Deaconess Health System Chooses Sectra as Enterprise Imaging Vendor
News | Enterprise Imaging | November 02, 2018
International medical imaging information technology (IT) and cybersecurity company Sectra will install its enterprise...
Carestream Spotlights Healthcare IT and Imaging Systems at RSNA 2018
News | Information Technology | October 31, 2018
Carestream announced it will be displaying several imaging and healthcare information technology (IT) offerings at the...
IMRIS, Siemens Strengthen Collaboration in Hybrid OR Neurosurgical Market
News | Hybrid OR | October 24, 2018
IMRIS, Deerfield Imaging, in partnership with Siemens Healthineers, announced a strengthened collaboration to advance...